3rd Annual Heart in Diabetes (HiD)

3rd Annual Heart in Diabetes (HiD) is organized by The Metabolic Institute of America (TMIOA) and will be held from Jul 12 - 14, 2019 at Loews Philadelphia Hotel, Philadelphia, Pennsylvania, United States of America. This CME Conference has been approved for a maximum of 24.75 AMA PRA Category 1 Credit(s)™.

Target Audience:
Cardiologist Endocrinologists, Nephrologists Diabetologists, Lipidologists Internists, Family Clinicians, and other clinicians who are interested in the Heart in Diabetes.

Conference Description:
This CME program is a unique medical conference designed to evaluate the state-of-the-art clinical research of heart disease in diabetes and its implications on practice. HiD will bring together world-renowned clinical leaders in Diabetes and Cardiovascular Disease, while aligning cardiologists, endocrinologists, lipidologists, nephrologists and hepatlogists in developing a multi-disciplinary, comprehensive understanding of today's clinical science on the management of high-risk patients.

Recent trials have demonstrated a cardiovascular benefit from anti-hyperglycemic, lipids, HTN and inflammation agents in people with diabetes. However, among practicing professionals, including experts in the field, there is a gap in understanding the implications of these new developments and their impact in managing these patients. 

The meeting provides a platform to address the clinical science of the Heart in Diabetes by providing current information and research, while highlighting implications on practice and evaluating it from the cardiology, endocrine/diabetes, and kidney points of view. Topics will include: Lipids, Glucose, ACS, CHF, Atherosclerosis, Vascular, the Kidney, Coagulation, Arrhythmia, fatty Liver and other related conditions. The meeting will promote discussion and interaction among the various specialists in how they develop their respective approaches to the management and prevention of Heart Disease in Diabetes.

Conference Objectives:
Upon completion of this meeting, participants should be able to:
• Describe the relationship between diabetes, obesity, and the heart
• Explain the roles of diabetes and obesity in the development of kidney disease, retinopathy, CVD, and arrhythmia
• Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia
• Understand cardiovascular outcomes trials (CVOT) and the role of real-life big data in assessing management
• Evaluate antihyperglycemic CVOT results, specifically the use of SGLT2 inhibitors and GLP1 RAs to reduce cardiovascular morbidity and mortality in patients with T2D
• Understand CHF in diabetes to implement best practices for the management of CHF
• Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
• Explain the role of lipids, in particular LDL-C and non-HDL-C, in the development of atherosclerosis
• Describe the role of PCSK9 in lipid homeostasis and the impact of monoclonal antibody therapy with PCSK9 inhibitors on cardiovascular disease
• Understand risk categories and determine appropriate targets of lipid-lowering therapy as outlined in the AACE 2017 Dyslipidemia Management Clinical Guidelines
• Appropriately diagnose and treat hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes
• Address the proper anticoagulation agents in the management of the high-risk patient
• Understand the combination treatments of CHF, hypertension, and lipid disorders
• Discuss the role of combination therapy in the management of obesity and diabetes with a focus on incretin- and SGLT2 inhibitor–based treatment